On April 28, the FDA initiated two real-time clinical trials and launched a pilot program for AI-enabled early-phase studies. The agency now views continuous data sharing as a regulatory priority, offering neuroscience a critical opportunity. The field, long hindered by high failure rates in drug development, stands to benefit significantly from this shift. Phase 3 failures in Parkinson’s and Alzheimer’s—marked by near-chartless primary endpoint misses—highlight structural flaws in current trial designs. Even rare approvals, like donanemab, often lack real-world adoption. Parkinson’s remains without a disease-modifying therapy despite decades of effort.
The 90% attrition rate in drug candidates underscores systemic challenges. Standard endpoints in Parkinson’s—such as OFF time, MDS UPDRS Part II progression, and fall frequency—are captured episodically, introducing noise and delay. These measures, reliant on infrequent clinic visits, struggle to detect subtle changes. A year of disease progression may fall below detection thresholds. This necessitates longer, larger trials, perpetuating high costs and delays. Improved measurement could redefine trial parameters.
AI’s role is not to replace trials but to enhance early-stage decision-making. The FDA’s Real-Time Continuous Trial (RTCT) initiative focuses on identifying responsive patients, meaningful signals, and evidence of therapeutic effect. Neurology sponsors must align with this approach, leveraging digital tools to capture validated endpoints with greater sensitivity. Wearables and digital phenotyping can transform raw data into actionable insights, reducing reliance on static clinic-based metrics.
Why Parkinson’s Phase 3 Trials Are Prolonged
Current motor endpoints in Parkinson’s, though clinically valid, are measured through episodic methods that flatten disease variability. UPDRS progression occurs gradually, often within the noise of single-visit assessments. True progression may be obscured, requiring extended trial durations. Continuous monitoring could capture real-time fluctuations, enabling earlier detection of therapeutic responses and smaller, more efficient trials.
Digital tools reveal day-to-day disease dynamics, converting raw data into signals and evidence. This layered approach—data to signals to evidence—separates utility from redundancy. Relying on endpoint-focused designs risks regulatory misalignment. Sustainable progress demands integrated systems that prioritize continuous measurement over static assessments.
Precision Over Broad Diagnoses
Parkinson’s heterogeneity—manifesting as tremor-dominant, postural instability, or cognitive subtypes—challenges uniform trial enrollment. Heterogeneous populations dilute treatment effects, masking subgroup responses. Companion diagnostics, prevalent in oncology, offer a blueprint. Genomic tools now enable stratification of Parkinson’s-related genes (e.g., GBA, LRRK2), while continuous phenotyping identifies responders. Success hinges on integrating these tools into trials before protocol finalization.
A failed trial might reveal efficacy in a specific subgroup if designed to detect it. Traditional approaches, which prioritize population averages, often discard such opportunities. Precision frameworks could convert program failures into targeted therapies, as seen in oncology’s biomarker-driven models.
Critical Questions Before Protocol Locking
Sponsors must evaluate three key elements before finalizing trials. First, are endpoints measured continuously or only at visits? Second, does enrollment stratify by genetic or phenotypic subtypes? Third, can negative results still yield meaningful responder analyses? These steps ensure trials are engineered for success, reflecting the FDA’s emphasis on actionable data.
Redefining Success in Parkinson’s
In coming years, a patient may receive a Parkinson’s therapy validated through genomic coding and digital phenotyping within a registrational trial. This would mark the end of the 20-year approval drought. The technology exists; adoption depends on sponsors prioritizing innovation in protocol design. The FDA’s RTCT initiative signals a clear path forward—neurology must embrace it to avoid further setbacks.